Raf/MEK/ERK pathways are activated in many tumors (prostate, breast, leukemia, melanoma, thyroid), which transmit the signals from cell surface receptors to transcription factors and can be exploited for therapeutic intervention (McCubrey et al., 2007[36]). Here, CD177 is linked to melanoma.